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 High intensity focused ultrasound in the treatment of breast fibroadenomata: 
Results of the HIFU-F feasibility trial 
Objectives: Breast fibroadenomata (FAD) are the most common breast lumps in women. High intensity 
focused ultrasound (HIFU) is a non-invasive ablative technique that can be used to treat FAD but is 
associated with prolonged treatment times. In the HIFU-F trial, we evaluated the change in volume over 
time with circumferential HIFU treatment of FAD and compare this to no treatment. 
Methods: Patients ≥18 years, diagnosed with symptomatic, palpable FAD, visible on ultrasound (US) 
were recruited. Twenty patients were treated using the US-guided-HIFU under local anaesthesia. Another 
20 participants underwent an US six months after diagnosis. Outcome measures included: reduction in 
treatment time compared to whole lesion ablation; feasibility to achieve a 50% reduction in volume after 
six months; decrease in volume compared to a control group and reduction in symptoms.  
Results: Circumferential ablation reduced the mean treatment time by 37.5% (SD 20.1%) compared to 
whole lesion ablation. US demonstrated a significant mean reduction in FAD volume of 43.5% (SD 
38.8%; p=0.016, paired t-test) in the HIFU group compared to 4.6% (SD 46.0%; p=0.530) in the control 
group after six months. This mean reduction in FAD volume between the two groups was significant in 
favour of the HIFU group (p=0.002, grouped t-test). Pre-treatment pain completely resolved in six out of 
eight patients six months post-treatment. 
Conclusion: Circumferential HIFU ablation of FAD is feasible, with a significant reduction in pain and 
volume compared to control participants. It provides a simple, non-invasive, outpatient – based alternative 
to surgical excision for FAD. 
ISRCTN registration: 76622747 
Keywords: High intensity focused ultrasound, breast, fibroadenomata, ablative technique, ultrasound.  
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 Introduction 
Breast fibroadenomata (FAD) are the most common breast lumps in women and one in ten will 
develop a FAD during their lifetime. [1, 2] Patients with FAD present with a palpable lump, 
detected during self-examination or incidentally during screening mammography or other 
imaging of the chest area. [2, 3] Ultrasound (US) is the main diagnostic method used, but 
confirmation can only be obtained by core needle biopsy (CNB). [1-3] The management of FAD 
is generally limited to patient reassurance. Excision, either surgically or radiologically (e.g. by 
vacuum-assisted mammotomy (VAM)) is typically reserved for those women with symptomatic 
or rapidly growing lesions and results in scarring which may compromise cosmesis. [1-3] 
Furthermore, surgical excision is most commonly performed under general anaesthesia with its 
potential complications, in addition to any possible surgical complications. VAM is licensed for 
diagnostic purposes (not therapeutic) but is nevertheless increasingly used as an alternative to 
surgery. VAM is performed under local anaesthesia, is invasive, is not suitable for all FAD and 
may not always be successful in removing the whole FAD due to a decrease in visibility during 
treatment. 
High intensity focused ultrasound (HIFU) is a novel non-invasive ablative technique 
which has been used for the treatment of liver, kidney, prostate, brain, bone and breast tumours. 
[4-6] During HIFU treatment, an US beam generated by a piezoelectric US transducer 
propagates through tissue as a high-frequency pressure wave. [5, 7] The beam is focused onto the 
target tissue and the energy from the beam elevates the temperature of the focus area to 60-95⁰C 
within seconds without causing damage to the directly adjacent tissues, leading to localised 
protein denaturation and coagulative necrosis. [5, 7, 8] Depending on the type of application and 
penetration depth, US beams with a frequency in the range between 0.5-4.0 MHz are used. [4, 5] 
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 HIFU is capable of providing a completely non-invasive therapy, avoiding the potential 
complications associated with general anaesthesia and surgery. [9] 
A systematic review by Peek et al. [10] on HIFU in the treatment of breast tumours 
showed that the most significant drawback with the current HIFU technique is the prolonged 
treatment time, which ranged from 78 and 171 minutes. The aim of the HIFU-F trial was to 
perform circumferential HIFU treatment to isolate the FAD from its blood supply, resulting in 
necrosis and a reduced treatment time. [11] Furthermore, this is the first case-control study 
comparing the change in FAD volume after six months with and without HIFU treatment.  
 
Materials and Methods 
A prospective proof-of-principle trial was set up to initially recruit and treat 20 consecutive 
patients with circumferential HIFU. A further 20 unselected patients were invited to have a 
control US scan, six months after their initial US scan to determine the natural change in size of 
their FAD when treated conservatively. Written informed consent was obtained from all patients. 
This study received approval from the national Research Ethics Committee (13/LO/1221).  
Patient selection 
Patients were included if they were 18 years of age or older and had visited the one-stop Breast 
Clinic at Guy’s Hospital with a symptomatic FAD – either a palpable lesion or pain developing 
from this lesion – which was visible on US. Patients more than 25 years of age required 
histological confirmation of the FAD diagnosis on needle core biopsy. Patients were excluded if 
they had an FAD of 1 cm or less, were pregnant or lactating, had received laser or radiation 
JU
ST
AC
CE
PT
ED
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 04
:43
 05
 A
ug
us
t 2
01
6 
 therapy to the ipsilateral breast, had breast implants, if epithelial atypia was seen or if there was 
any suspicion of phyllodes tumour. No other exclusions were applied.  
Any retro-areolar FAD will be treated in a lateral position. In the case of a FAD located 
close to the skin or pectoralis major muscle (< 5mm), local anaesthesia will be injected between 
the FAD and the skin and / or muscle. The optimal target volume will be selected in order to 
avoid thermal damage to skin and pectoral muscle and to cover the most central part of the FAD. 
All eligible patients were identified in three ways: (1) at the multi-disciplinary meeting, where all 
patients were discussed in which CNB or fine needle aspiration cytology was performed, (2) 
patients scheduled for surgical excision of a FAD and (3) patients referred to the breast clinic 
with a symptomatic breast lump requesting treatment. All patients were approached in the breast 
clinic or by telephone and received a patient information sheet (PIS) if interested in participating 
in the HIFU-F trial.  
Primary outcome measures were the change in treatment time compared to whole lesion 
ablation (based on the treatment plan), feasibility of achieving a 50% reduction in volume on US 
after six months, and the decrease in volume on US compared to an observation only group 
(control). Secondary outcomes were the complication rate and patient recorded outcome 
measures (palpable FAD, pain symptoms before and after treatment measured with visual analog 
scale (VAS) prior and after treatment).  
HIFU treatment 
Patients were treated using the US-guided-Echopulse device (Theraclion Ltd, Malakoff, France) 
which is dedicated for the treatment of breast FAD and thyroid nodules. The device contained a 
cooling and coupling disposable unit to cool the skin and prevent burning. Breast lesions were 
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 ablated under real-time US guidance using a 7.5-12 MHz diagnostic US transducer. Therapeutic 
US energy was produced by a 56 mm diameter 3.0 MHz treatment transducer with a central hole 
measuring 11 mm for the coaxial imaging transducer. The transducer ablates an oval tissue 
volume of approximately 9 mm in length and 2 mm in width.  
All patients were treated as a day-case and under subcutaneous local anaesthesia (1.0% 
Lidocaïne with adrenaline and 0.25 - 0.5% Bupivacaïne, ratio 1:1, mean 23.1 ml, SD 8.1 ml). In 
the case of FAD located close to the muscle, anaesthesia was injected deep, between the muscle 
and the FAD, in order to avoid pain resulting from heating of the pectoralis major muscle. 
Depending on the position of the FAD and the size of the breast, the patient was placed in either 
a supine or lateral position and an immobilisation system was used to fix the breast. After an US 
scan with a handheld probe to locate the FAD, the device head was positioned on top of the FAD 
to outline the lesion and the skin in the radial and anti-radial view (Fig. 1). For every radial slice, 
treatment pulses were visualised and the skin and FAD outlines were adjusted when required. 
The procedure started with a single pulse in the centre of the FAD to determine the right energy 
level, identified by a hyper-echoic mark visible right after or during administration of the pulse. 
During subsequent treatment pulses no hyper-echoic mark was required and pulses were not 
repeated when no mark was seen. The HIFU device calculates the energy and power level of 
each pulse during treatment. In the HIFU-F study, only the circumference was ablated; two 
circumferential rings around the FAD were treated and the centre of the FAD was deselected 
(Fig. 2). The Echopulse device treats only one central, top or bottom disc shaped target volume 
(curved or horizontal) of the FAD during a treatment session. Most FAD require only one target 
volume as this is sufficient to cover the whole lesion. After the final pulse, the patient’s skin was 
observed for any treatment changes. Patients were then discharged following hospital protocol. 
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 Patients were asked to provide a pain score after the procedure for intra- and post-treatment pain 
on a VAS of 0-10.  
Treatment time from the beginning of the first to the end of the last pulse administered 
was recorded, along with the number of pulses delivered. The average time to deliver a treatment 
pulse was calculated (including any delays between pulses due to treatment pauses) and used to 
estimate total treatment time required for delivering the pulses required to cover the whole 
lesion. 
Follow-up  
Patients were followed up at two weeks, three and six months with physical examination and US 
scan. The ultra-sonographers performing the US scans were not blinded but the consultant was 
blinded from the US results during physical examination. The decrease in FAD volume was 
determined using standard formulae in which V is the FAD volume and A, B and C are the 
longest diameters of the FAD measured on US. [12]  
𝑉 =
4
3
∗ 𝜋 ∗ (
1
2
𝐴) ∗ (
1
2
𝐵) ∗ (
1
2
𝐶) 
Control group 
A further 20 patients were consecutively recruited, without matching with the HIFU group, to 
determine the natural course in volume change of their FAD, as assessed by US, six months after 
initial presentation. Patients were recruited using the same inclusion and exclusion criteria as the 
HIFU treatment group. The change in volume of these patients was compared to the change in 
volume in the HIFU treatment group.   
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 Statistical analysis  
Statistical analysis was performed using IBM SPSS statistics version 23. A paired t-test and 
Wilcoxon signed rank test were used to determine the significance of the reductions in FAD 
volumes over time. A Kolmogorov-Smirnov test was used to determine if there were any 
differences in distribution between the HIFU and the control group in terms of age and initial 
FAD volume. A grouped t-test, Levene’s test and Mann Whitney U-test were used to determine 
if there was a significant difference in volume reductions between the HIFU and the control 
group. 
 
Results 
Patients screened 
A total of 262 patients with FAD were screened prospectively at the MDM between January, 
2014 and October, 2014. Of these 262 patients, 122 patients (45.3%) met all inclusion criteria, 82 
patients were contacted and 20 patients (7.6%) agreed to participate in the HIFU-F trial. 
Patient characteristics 
These 20 patients (HIFU group) with symptomatic palpable FAD (eight patients with pain 
related to FAD) successfully underwent circumferential HIFU treatment. Patients had a mean 
age of 30.3 years (SD 7.5 years, range 18-45 years) and mean volume of 7.3 cm
3
 (SD 10.1 cm
3
, 
range 0.4-44.0 cm
3
). A further 20 patients (control group) with biopsy confirmed FAD 
successfully underwent a follow-up US six months after initial diagnosis. Patients had a mean 
age of 31.3 years (SD 6.5 years, range 21-46 years), not significantly different to the HIFU group 
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 (P=0.819, Kolmogorov-Smirnov test, Fig. 3). The mean volume was 3.0 cm
3
 (SD 4.1 cm
3
, range 
0.4-18.7 cm
3
), again not significantly different to the HIFU group before treatment (P=0.082, 
Kolmogorov-Smirnov test, Fig. 3). 
HIFU treatment 
Two circumferential rings were successfully treated in ten patients; one circumferential ring was 
successfully treated in nine patients (five of these almost completed treatment of two rings apart 
from one or two pulses) due to patient movement or pain during treatment. One patient was 
unable to tolerate a complete circumferential ring of pulses due to pain in her arm (repetitive 
strain injury). Two patients underwent surgery post-HIFU due to absence of decrease in FAD 
size three and 12 months after HIFU treatment, respectively. Histology demonstrated residual 
FAD but with prominent areas of fibrosis (Fig. 4). Mean energy per HIFU treatment was 134.6 
Joule (SD 19.3 Joule) and mean power per treatment was 33.3 Watt (SD 4.8 Watt).  
Treatment times 
The mean recorded treatment time from first sonication to last sonication was 34.6 minutes (SD 
10.5 minutes). Circumferential ablation reduced the treatment time by an average of 37.5% (SD 
20.1%) compared to the treatment time calculated for whole lesion ablation. Total treatment 
recorded time of patients being in the theatre is 68.7 minutes (SD 16.2 minutes). 
Pain symptoms 
Eighteen of 20 patients experienced some discomfort or a burning sensation during the 
procedure. The mean maximum pain VAS score during treatment was 6.4 (SD 3.2). By moving 
to another part of the FAD, the treatment was continued with agreement of the patient in 17/18 
patients. Mean maximum pain VAS score immediately after treatment was 1.6 (SD 1.9).  
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 At six months follow-up, six out of eight patients who experienced pre-treatment pain had 
complete resolution of their symptoms. Two patients developed post-treatment pain, which 
resolved within three months. 
Complications 
Short-term complications (Fig. 5) at two weeks were: ecchymosis (n=9), erythema (n=6), hypo-
pigmentation of the skin (n=1), dimpling of the skin (n=1), numbness of the skin (n=1) and a 
superficial first-degree skin burn (n=1). All short-term complications completely resolved within 
the first month post-treatment without the need for intervention. Hyper-pigmentation was found 
at three months in six patients and persisted at six months in four patients. 
Volume measurements by US 
US scans at two weeks post-treatment showed hyper-echogenicity and oedema at the 
circumference of the lesion in some patients. The FAD had a mean volume of 6.1 cm
3
 (SD 8.4 
cm
3
); a mean decrease in volume of 16.8% (SD 19.3%) (p=0.021, paired t-test; Z=-2.688, 
p=0.007, Wilcoxon signed rank test). At three months the volume was 5.0 cm
3
 (SD 6.5 cm
3
); a 
mean decrease in volume of 30.9% (SD 52.7%) (p=0.022; Z=-2.535, p=0.11). At six months the 
mean volume was 4.6 cm
3
 (SD 6.4 cm
3
), a decrease in volume of 43.5% (SD 38.8%) (p=0.016; 
Z=-2.741, p=0.006) (Fig. 6, table 1a). At six months, a total of four patients had no palpable 
lesion. 
Control group 
At the six month US scan the mean volume was 2.6 cm
3
 (SD 2.3 cm
3
), a non-significant change 
in size of 4.6% (SD 46.0 %) (p=0.530, paired t-test; Z=-0.073, p=0.709, Wilcoxon signed rank 
test; table 1b). Compared to the control group the HIFU group showed a significant change in 
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 volume over a period of six months (p=0.002, grouped t-test; U=58, p=0.001, Mann Whitney U-
test). 
 
Discussion 
The current treatment of symptomatic or rapidly growing FAD is surgical excision, however 
scarring can compromise the cosmetic outcome [1-3] and VAM is licensed for diagnostic 
purposes (not therapeutic) but is nevertheless increasingly used as an alternative to surgery. An 
alternative non-invasive technique is therefore required, which allows the patient to undergo 
treatment without scarring, surgery and general anaesthesia and which allows for intra-operative 
visibility of the lesion and a low side-effect profile.  
HIFU has demonstrated effectiveness in the treatment of benign breast disease using total 
lesion ablation. [13-15] Hynynen et al. [13], treated eleven FAD and found a decrease in volume 
of 32% (1.9 to 1.3 cm³) measured on T2-weighted magnetic resonance imaging after six months. 
Patients were treated with local anaesthesia and mild sedation. Slight pain was reported in four 
patients, mild pain in two and severe pain in one patient. No complications other than pain and 
swelling were reported. More recently, Kovatcheva et al. [14] found a FAD volume decrease of 
59.2±18.2% (n=42) after six months on US and reported complete resolution of pain in 18 
patients who had pre-treatment pain. These patients were treated under conscious sedation and 
the mean pain score during treatment was 29.7 (SD 27.5) using a 0-100 mm VAS scale. Three 
superficial skin burns with blister like aspects, and single cases of subcutaneous induration and 
hyperpigmentation were reported. Cavallo Marincola et al. [15] found a decrease of 50% at three 
months (n=10). Local anaesthesia and conscious sedation were administered during treatment. 
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 The number of patients with pre-treatment pain was not reported, but none of the patients had 
pain at six months. No complications were observed at three months apart from swelling and 
hardness of the treated area.  
A systematic review by Peek et al. [10] showed that the most significant drawback with 
HIFU was the prolonged treatment time associated, which ranged between 78 and 171 minutes. 
The HIFU-F trial demonstrated that a high mean volume reduction of 43.5% (SD 38.8) can be 
achieved at six months with a circumferential ablation, whilst reducing mean treatment times to 
37.4 minutes (SD 11.9). This reduction in treatment time made it possible to perform the 
procedure under local anaesthetic only, without the need for sedation – unlike previous studies. 
The treatment time for whole lesion ablation was calculated using the average time to deliver a 
single pulse, recorded during circumferential HIFU ablation. Although this included some 
variability caused by patient movement and repositioning, the calculated time might still be an 
under-estimation as patients with larger tumours and therefore a longer HIFU treatment time, 
may move more and require more time for repositioning. 
It is likely that the circumferential ablation is successful through targeting the ‘feeding 
vasculature’ to the FAD. This could warrant the use of Doppler US imaging to target feeding 
vessels in real-time in future studies. In four patients an increase in FAD volume was seen on US 
post-treatment and in one patient the FAD did not change in size. A hypothesis about the 
increase in FAD size is that treatment could not be completed due to pain during treatment (n=2), 
furthermore HIFU only treats a disk and not the top and bottom of the FAD, due to distance 
restrictions to the skin (>5mm) and pectoralis major (>5mm). Two patients with increased FAD 
underwent surgical excision, one was happy to leave the FAD alone and the last patient was lost 
to follow-up. 
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 After HIFU treatment, the FAD initially increases in size due to inflammation and 
oedema. This resolves within the first two weeks post-treatment. As seen in other trials [14], the 
largest decrease in size is observed between the third and sixth month, followed by a slower 
decrease between six and 12 months. It is important for patients to be aware of this gradual 
decrease in size, as opposed to the instant removal of the lump with surgical excision, as patients 
might be anxious about the persistence of a lump. Patient selection is therefore a very important 
factor. It is important for patients to be aware of the gradual decrease in size of the FAD after 
treatment and achieving impalpability of the lump might not always be achievable.  
Six out of eight patients showed a resolution of pain symptoms post-treatment, this is 
most likely due to the treatment damaging the local sensory pain receptors thereby blocking the 
pain feedback pathway. Clearly FADs can cause pain and HIFU can be used if the pain is located 
in the FAD. Kovatcheva et al. [14] as well reported a resolution in FAD pain after HIFU 
treatment. For the control group the only measured outcome was change in volume and we did 
not assess pain scores. Volume was evaluated using an US to determine the FAD size after six 
months. Patients of both the control and the HIFU groups were recruited using the same 
inclusion and exclusion criteria without selection. However, since this study was not randomised, 
the control group might have been less symptomatic compared to the HIFU group, since they did 
not request treatment. 
After six months the FAD became impalpable in four patients in the other 16 patients, the 
lump was still palpable but was more diffuse and therefore harder to feel. During follow-up, 
however, patients were not concerned about the residual lump. On US the FAD was seen to be 
fragmented in some cases and more integrated with the surrounding tissue. Patients were very 
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 conscious of their treated FAD due to their participation in the trial, sometimes resulting in an 
over-estimation of the size of the lesion, compared to the size measured on US.  
All complications recorded at two weeks completely disappeared within a month post-
treatment without the need of any additional treatment. One patient developed a superficial first-
degree skin burn during HIFU treatment; caused by either the micro-foam used for 
immobilisation of the breast or air in-between the probe and the skin. The patient required no 
treatment and the burn completely resolved within one month post-treatment. This patient 
attended the HIFU clinic one month later for HIFU treatment of a contralateral FAD. When 
placing the treatment probe on the skin, care is needed to make sure the probe is not placed on 
the site of local anaesthesia injection. Small air bubbles might be left at this site and when 
located in the US beam this might cause cavitation and in the worst case cause a blister or skin 
burn. Altered skin pigmentation was seen in six patients at three months and in three patients at 
six months. Skin pigmentation was more common in patients with a darker pigment colour, 
however skin pigmentation also occurred in a patient with pale skin.  
Altered skin pigmentation can be caused by a high treatment power or a shorter distance 
between the FAD and the skin resulting in overheating of the skin, however the mean treatment 
power and distance between skin and FAD within the HIFU group were less than the average for 
the complete group (33.0 W/site vs 33.3 W/site and 3.7 mm vs 4.7 mm for respectively the 
patients altered with skin pigmentation and the HIFU-F trial group). Another possible 
explanation is that these patients did not feel much discomfort during treatment and therefore 
treatment could continue without interruptions, resulting in overheating of the skin. This theory 
could be correct for the first three patients but the latter three patients did feel more pain, 
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 resulting in more treatment breaks. Further investigation is required to determine the cause of the 
altered pigmentation and it is important to inform future patients of this potential complication.  
Compared to the control group, in the HIFU group there was a significant reduction in 
volume of the FAD over a period of six months. The significant difference in volume 
demonstrated that HIFU as a non-invasive technique can be used for the treatment of FAD. 
There are however a few drawbacks of the technique, even with assistance of an 
immobilisation system, it was difficult to position and immobilise patients with smaller breasts. 
A more advanced immobilisation system is required to be able to perform more accurate 
treatment and faster positioning of the patient. Furthermore, even with local anaesthesia, patients 
were found to have discomfort during the treatment. This might be a result of pulses being 
administered on local sensory pain receptors. This would also explain why, when returning to 
this location, this area would not be as uncomfortable as before. Treatment pulses given at the 
border of the FAD and the surrounding tissue could be more painful as well. More anaesthesia in 
the form of pre-treatment oral painkillers, topical crème or pectoral blocks should be evaluated in 
future studies.  
The ideal patient for HIFU treatment would therefore be one who has a symptomatic 
palpable FAD located at least 5 mm from both the skin and the pectoralis major and with a size 
of about 10-30 mm. These inclusion criteria are similar to those used for VAM. Furthermore, 
patients should accept an approximated 50% decrease in volume over a period of six months as 
an alternative to surgical scarring.  
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 Conclusion 
Circumferential HIFU ablation of FAD is feasible with a significant reduction in treatment time 
(mean 37.5%, SD 20.1) and a significant reduction in volume of the lesion at six months (mean 
43.5%, SD 38.8%). Furthermore, a resolution of pain symptoms (6/8 patients) and minor short-
term complications were found at six months follow-up. HIFU has a role in the treatment of 
FAD, which requires further economic and clinical evaluation. 
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 Table 1. Volume changes during six months follow-up in (a) HIFU treatment group and (b) 
control group. 
Figure 1. HIFU treatment of breast FAD. 
Figure 2. Treatment planning and final treatment. From left to right: (1) Manual drawing of 
outline of FAD (blue) and skin (red) on touchscreen unit in radial and anti-radial position and 
number of treatment pulses (white) calculated by the Echopulse; (2) Radial view of target 
volume with treatment pulses (white cylinders) calculated by the Echopulse; (3) Application of 
treatment pulse in centre of FAD; (4) Final treatment of two circumferential rings, showing 
completed pulses (green) and deselected pulses (grey). 
Figure 3. Box and Whisker plot for HIFU treatment and Control group (untreated) demonstrating 
pre-treatment volume (Blue) and age (Green) of the patients. 
Figure 4. Histopathology of excised FAD treated with HIFU showing fibrous scarring on low (L) 
and high power (R). 
Figure 5. Short term complications (a + b) two images of ecchymosis at two weeks, (c) hyper-
pigmentation at three months and (d) first-degree skin burn at two weeks post-treatment. 
Figure 6. Change in volume per patient at two weeks, three and six months follow-up (in %). 
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 Table 1: Volume changes during six months follow-up in (a) HIFU treatment group and (b) control 
group. 
(a) Volume (mean±SD, range) Change in volume (mean±SD, range) Significance 
Pre-treatment 7.3±10.1cm
3
 (0.4-44.0cm
3
) - - 
2 week follow-up 6.1±8.4cm
3 
(0.3-37.8cm
3
)
 
16.8±19.3% (↑27.1%-↓41.2%) P=0.021* 
3 month follow-up 5.0±6.5cm
3
 (0.1-28.2cm
3
) 30.9±52.7% (↑158.6%-↓77.8%) P=0.022* 
6 month follow-up 4.6±6.4cm
3
 (0.1-26.5cm
3
) 43.5±38.8% (↑58.9-↓80.5%) P=0.016* 
* Significant difference in change of volume (p<0.05, paired t-test). 
 
(b) Volume (mean±SD, range) Change in volume (mean±SD, range) Significance 
Pre-treatment 3.0±4.1 cm
3
 (0.4-18.7 cm
3
) - - 
6 months follow-up 2.6±2.3 cm
3
 (0.2-9.7 cm
3
) 4.6±46.0% (↑66.3 -↓93.5%)* P=0.434* 
* No significant difference in change of volume (p>0.05, paired t-test). 
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